Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induce
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/29/2014)... MA (PRWEB) July 30, 2014 ... (UC) and collaboration company, is proud to announce ... account management positions in their Boston, Charleston and ... response to the increased demand for hosted solutions, ... operational efficiency and reduce cost. , SoundConnect was ...
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... that provides innovative genetic analysis solutions, and Mayo ... laboratory services in the United States ... testing patents and applications. "We have great ... patient care, and we welcome the opportunity to partner ...
(Date:7/29/2014)... of researchers has created a new way of ... These surfaces, made by self-assembly of carbon nanotubes, ... including controllable mechanical stiffness and strength, or the ... , "We have demonstrated that mechanical forces can ... three-dimensional microstructures, and that we can independently control ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4A new way to make microstructured surfaces 2
... small-molecule ... -, - Lead compound AEG40826 works synergistically with HGS TRAIL receptor ... drugs -, - IAP inhibitors also show promise alone and in ... cancer agents across broad range of cancers -, ROCKVILLE, Md. and MONTREAL, ...
... Inc. (OTC Bulletin Board: NWBO; AIM: NWBS ... Lonza Group AG has,withdrawn all claims of ... NWBT DCVax(R) products other than DCVax(R)-Prostate.,Lonza had ... infringed,certain gene expression technology patents held by ...
... Helix BioPharma Corp.,(TSX, FSE: "HBP") today announced ... for gross proceeds of CDN$16,867,200., About ... is a biopharmaceutical company specializing in,the field ... developing innovative,products for the prevention and treatment ...
Cached Biology Technology:Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 2Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 3Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 5Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 6Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 2Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 3Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 4Helix BioPharma closes $16.9 million private placement of common shares 2
(Date:7/30/2014)... been awarded the Scientific Committee on Antarctic Research,s ... , SCAR, an inter-disciplinary international science body, initiates, ... in the Antarctic region, and on the role ... The organisation also provides scientific advice about Antarctica ... the region. , The medal is open internationally ...
(Date:7/30/2014)... the roughly 3,000 pieces is still in its infant ... will be of major significance. "Amazingly often, we are ... Fushun amber that we found in Baltic amber," explained ... Baltic amber comes from the Baltic Sea region, which ... finds are, e.g., the coastal regions of Mecklenburg, Poland ...
(Date:7/29/2014)... BELLINGHAM, Washington, USA The advanced optical methods and ... are driving a revolution in the neurosciences were the ... published by SPIE, the international society for optics and ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... science prize was today awarded to a researcher who is looking ... someone in a noisy place, such as a party or bar, ... these situations. , Not being able to hear a person's voice ... most common problems for Britain's nine million people with a hearing ...
... Houston, Texas have found two bacterial muscle infections common ... the emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), according ... of Clinical Infectious Diseases, now available online. , Staphylococcus ... the skin or in the nose of a quarter ...
... two inexpensive technologies that may be able to prevent ... E. coli in contaminated spinach. , Together, these technologies ... first method uses a laser to detect and identify ... faster and one-tenth as expensive as current technology. ...
Cached Biology News:Train your brain to hear your friends at a party 2Train your brain to hear your friends at a party 3Train your brain to hear your friends at a party 4Study shows antibiotic-resistant bacteria responsible for increase in muscle infections 2Researchers develop technologies to devour food pathogens 2Researchers develop technologies to devour food pathogens 3
... Maxi Kit provides a fast and simple ... Triton X-100 and other detergents from ... using Norgens patented protein resin as an ... processing 0.25 - 8 mg of either ...
Values of steady state parameters for enzyme activities are determined....
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... Nucleic acid hybridization Preparation Reconstitution: ... BSA, 50 mg ficoll and ... 5 ml of water yields ... molecular biology Density: 1.00 g/mL ...
Biology Products: